IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS

被引：0
|
作者：
Kovtun, Y. [1 ]
Jones, G. [1 ]
Harvey, L. [1 ]
Rui, L. [1 ]
Audette, C. [1 ]
Liu, F. [1 ]
Bai, C. [1 ]
Wilhelm, A. [1 ]
Yoder, N. C. [1 ]
Adams, S. [1 ]
Goldmacher, V. S. [1 ]
Chari, R. [1 ]
Chittenden, T. [1 ]
机构：
[1] ImmunoGen Inc, Waltham, MA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB582
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
    Daver, Naval Guastad
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Todisco, Elisabetta
    Tarella, Corrado
    Martinelli, Giovanni
    Erba, Harry Paul
    Deconinck, Eric
    Sweet, Kendra L.
    Walter, Roland B.
    Levy, Moshe Yair
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David
    Konopleva, Marina
    Sloss, Callum Mortimer
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
    Lock, Richard B.
    Evans, Kathryn
    Randall, Joanna
    Erickson, Stephen W.
    Earley, Eric J.
    Neuhauser, Steven
    Stearns, Tim
    Philip, Vivek
    Teicher, Beverly A.
    Watkins, Krystal
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Smith, Malcolm A.
    BLOOD, 2022, 140 : 8983 - 8984
  • [23] IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
    Kovtun, Yelena
    Noordhuis, Paul
    Whiteman, Kathleen R.
    Watkins, Krystal
    Jones, Gregory E.
    Harvey, Lauren
    Lai, Katharine C.
    Portwood, Scott
    Adams, Sharlene
    Sloss, Callum M.
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert
    Wang, Eunice S.
    Pinkas, Jan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1271 - 1279
  • [24] Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models
    Fritz, Claire
    Portwood, Scott M.
    Adams, Julie
    Cronin, Tara
    Lutgen-Dunckley, Linda
    Martens, Brandon L.
    Sloss, Callum M.
    Watkins, Krystal
    Kovtun, Yelena
    Adams, Sharlene
    Wang, Eunice S.
    BLOOD, 2018, 132
  • [25] IMGN632, a CD123-Targeting ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively as a Triplet Regimen with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)
    Kuruvilla, Vinitha
    McCarthy, Rebecca
    Zhang, Qi
    Watkins, Krystal
    Adams, Sharlene
    Sloss, Callum
    Zweidler-McKay, Patrick
    Romanelli, Angela
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S208 - S209
  • [26] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
    Daver, Naval G.
    Erba, Harry P.
    Papadantonakis, Nikolaos
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [27] Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class
    Stelte-Ludwig, Beatrix
    Schomber, Tibor
    Izumi, Raquel
    Wong, Harvey
    Frigault, Melanie M.
    Rebstock, Anne-Sophie
    Ludwig, Sebastian
    Mithal, Arushi
    Johnson, Amy J.
    Hamdy, Ahmed
    BLOOD, 2023, 142
  • [28] IMGN779: A CD33-TARGETED ANTIBODY-DRUG CONJUGATE (ADC) UTILIZING A NOVEL DNA ALKYLATOR, DGN462, IS HIGHLY ACTIVE IN VITRO AGAINST PRIMARY PATIENT AML CELLS AND IN VIVO AGAINST AML XENOGRAFTS IN MICE
    Whiteman, K. R.
    Noordhuis, P.
    Schuurhuis, G. J.
    Kovtun, Y.
    Harvey, L.
    Audette, C.
    Maloney, E.
    Johnson, H. A.
    Fishkin, N.
    Ossenkoppele, G. J.
    Lutz, R. J.
    HAEMATOLOGICA, 2014, 99 : 293 - 293
  • [29] Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)
    Deckert, Jutta
    Ponte, Jose F.
    Coccia, Jennifer A.
    Lanieri, Leanne
    Chicklas, Sharon
    Yi, Yong
    Watkins, Krystal
    Ruiz-Soto, Rodrigo
    Romanelli, Angela
    Lutz, Robert J.
    BLOOD, 2014, 124 (21)
  • [30] INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Cortes, J.
    DeAngelo, D.
    Wang, E.
    Arana-Yi, C.
    Zweidler-McKay, P.
    Munteanu, M.
    Andreu-Vieyra, C.
    Erba, H.
    Blum, W.
    Traer, E.
    HAEMATOLOGICA, 2017, 102 : 217 - 218
12345